Onco-Innovations Announces Advancements in Polymer Development Program for ONC010

Vancouver, Canada — July 30, 2026 — Leads & Copy — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) announced progress in its collaborative polymer development program with Nanosoft Polymers, focusing on enhancing the consistency and uniformity of the polymer used in ONC010, the company's lead nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor. This work is a crucial part of the chemistry, manufacturing and controls (CMC) development for ONC010.

The program's core objective is to improve control over the polymer's polydispersity index (PDI), a key metric for molecular weight uniformity. Enhanced PDI control is anticipated to lead to more consistent polymer characteristics, improved nanoparticle formation, better formulation performance, and greater batch-to-batch manufacturing reproducibility. The ongoing efforts are dedicated to developing a robust manufacturing process for Onco's proprietary PEO-PBCL block copolymer, a vital component of the nanoparticle delivery platform for ONC010.

Onco and Nanosoft are also progressing with analytical characterization and scale-up activities. These initiatives are designed to help define critical manufacturing parameters and provide essential support for future good manufacturing practice (GMP) production and clinical development. Nanosoft has advanced multiple technical workstreams, establishing critical manufacturing parameters since the program's inception. Key areas of focus have included catalyst selection and reaction optimization to improve polymer consistency, alongside refinements in purification strategies and manufacturing efficiency.

Thomas O’Shaughnessy, Chief Executive Officer of Onco-Innovations, emphasized the significance of a scalable and reproducible polymer manufacturing process for the successful advancement of nanoparticle therapeutics. “We are pleased with the progress Nanosoft has made in advancing the optimization of our polymer platform and believe these activities further strengthen the manufacturing foundation supporting ONC010’s future development,” O’Shaughnessy stated. “By investing early in process optimization and analytical development, we are working to reduce manufacturing risk while positioning the program for future clinical and commercial scalability.”

The company anticipates that polymer process optimization, analytical characterization, and scale-up activities will continue over the coming months as part of its comprehensive CMC strategy for ONC010. These efforts are aimed at facilitating future technology transfer, GMP manufacturing, and regulatory submissions, while simultaneously enhancing long-term manufacturing robustness.

Dr. Islam Mohamed, Chief Medical Officer of Onco-Innovations, highlighted the critical need for precision in polymer engineering for nanoparticle therapeutics. “Nanoparticle therapeutics require the same level of precision in polymer engineering as they do in pharmaceutical development,” Dr. Mohamed said. “Building a well-characterized, reproducible polymer platform today can materially strengthen the quality of the final drug product and support a smoother path through regulatory review and clinical development.”

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. Onco has secured an exclusive worldwide license to patented technology targeting solid tumors.

Source: Onco-Innovations Limited